Q1 Earnings Estimate for GH Research Issued By HC Wainwright

GH Research PLC (NASDAQ:GHRS) – Analysts at HC Wainwright upped their Q1 2025 EPS estimates for GH Research in a research report issued to clients and investors on Tuesday, March 4th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of ($0.19) for the quarter, up from their prior forecast of ($0.22). HC Wainwright has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for GH Research’s current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for GH Research’s Q2 2025 earnings at ($0.20) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.24) EPS, FY2025 earnings at ($0.82) EPS, FY2026 earnings at ($0.88) EPS, FY2027 earnings at ($0.92) EPS and FY2028 earnings at ($0.46) EPS.

GH Research (NASDAQ:GHRS) last issued its earnings results on Thursday, February 27th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.06.

Several other analysts have also recently weighed in on the stock. Canaccord Genuity Group cut their price target on shares of GH Research from $31.00 to $28.00 and set a “buy” rating on the stock in a report on Monday, November 18th. Cantor Fitzgerald began coverage on shares of GH Research in a report on Thursday, February 13th. They issued an “overweight” rating and a $14.00 price target on the stock. Royal Bank of Canada began coverage on shares of GH Research in a report on Friday. They issued an “outperform” rating and a $31.00 price target on the stock. Finally, Stifel Nicolaus lifted their price target on shares of GH Research from $18.00 to $32.00 and gave the company a “buy” rating in a report on Thursday, February 27th. Six analysts have rated the stock with a buy rating, According to MarketBeat, GH Research presently has an average rating of “Buy” and an average price target of $30.67.

GH Research Stock Down 0.5 %

NASDAQ:GHRS opened at $10.50 on Friday. The stock has a market cap of $546.29 million, a P/E ratio of -13.29 and a beta of 0.94. The firm’s fifty day simple moving average is $10.73 and its 200 day simple moving average is $9.20. GH Research has a twelve month low of $6.00 and a twelve month high of $20.50.

Hedge Funds Weigh In On GH Research

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. RA Capital Management L.P. raised its position in shares of GH Research by 1.3% in the 3rd quarter. RA Capital Management L.P. now owns 6,686,689 shares of the company’s stock worth $44,734,000 after purchasing an additional 85,000 shares during the last quarter. Lynx1 Capital Management LP raised its position in shares of GH Research by 15.8% in the 4th quarter. Lynx1 Capital Management LP now owns 4,858,994 shares of the company’s stock worth $34,013,000 after purchasing an additional 663,100 shares during the last quarter. Diadema Partners LP purchased a new position in shares of GH Research in the 4th quarter worth about $711,000. Woodline Partners LP raised its position in shares of GH Research by 112.0% in the 4th quarter. Woodline Partners LP now owns 78,949 shares of the company’s stock worth $553,000 after purchasing an additional 41,711 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in shares of GH Research by 4.5% in the 4th quarter. Geode Capital Management LLC now owns 72,513 shares of the company’s stock worth $508,000 after purchasing an additional 3,092 shares during the last quarter. Hedge funds and other institutional investors own 56.90% of the company’s stock.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).